{"id":"prevenartm","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site erythema"},{"rate":"15-25","effect":"Injection site swelling"},{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-20","effect":"Fever"},{"rate":"30-40","effect":"Irritability/fussiness"},{"rate":"20-30","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prevenar conjugates capsular polysaccharides from multiple serotypes of S. pneumoniae to a protein carrier (CRM197), enhancing immunogenicity and T-cell dependent responses. This allows the vaccine to induce protective antibodies in both children and adults, preventing invasive pneumococcal disease including bacteremia, meningitis, and pneumonia caused by vaccine-covered serotypes.","oneSentence":"Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:03.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of invasive pneumococcal disease in adults ≥50 years of age"}]},"trialDetails":[{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT00488826","phase":"PHASE1","title":"Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Pneumococcal Infections","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PrevenarTM","genericName":"PrevenarTM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of invasive pneumococcal disease in adults ≥50 years of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}